These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 18639973)

  • 1. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.
    Eggener S
    Eur Urol; 2009 Mar; 55(3):616. PubMed ID: 18639973
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment.
    Carter HB
    Urology; 2009 Sep; 74(3):658; author reply 659. PubMed ID: 19716923
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Albertson PC
    Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Aus G
    Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    Malavaud B
    Eur Urol; 2008 Sep; 54(3):515-6. PubMed ID: 18585850
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    Rittmaster R
    Eur Urol; 2008 Sep; 54(3):514-5. PubMed ID: 18585846
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.
    Autorino R; Perdonà S; Di Lorenzo G
    Urology; 2010 Nov; 76(5):1076; author reply 1076-7. PubMed ID: 21056255
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
    Finney Rutten LJ
    Eur Urol; 2008 Jun; 53(6):1193. PubMed ID: 17709172
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment: factor that influence serum prostate-specific antigen levels in terms of maintaining quality within a PSA screening system.
    Ito K
    Eur Urol; 2007 Sep; 52(3):714. PubMed ID: 17849514
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment.
    Chong KT
    J Urol; 2009 Oct; 182(4):1348; discussion 1349. PubMed ID: 19683273
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment.
    Lin CC
    J Urol; 2009 Oct; 182(4):1348; discussion 1349. PubMed ID: 19683264
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment.
    van Renterghem KM
    J Urol; 2009 Oct; 182(4):1349; discussion 1349. PubMed ID: 19683263
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.
    Froehner M
    Eur Urol; 2008 Aug; 54(2):368-9. PubMed ID: 18006213
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.
    Stephan C; Jung K
    Eur Urol; 2008 Aug; 54(2):369-70. PubMed ID: 18006212
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of high-grade prostatic intra-epithelial neoplasia on total and percentage free serum prostate-specific antigen.
    Chahal R; Sundaram SK
    BJU Int; 2000 Jul; 86(1):147. PubMed ID: 10979730
    [No Abstract]   [Full Text] [Related]  

  • 16. Active surveillance for prostate cancer: has the time finally come?
    Aragon-Ching JB
    J Clin Oncol; 2010 Jun; 28(16):e265-6; author reply e267. PubMed ID: 20406916
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate cancers in the transition zone: Part 2; clinical aspects.
    Augustin H; Erbersdobler A; Hammerer PG; Graefen M; Huland H
    BJU Int; 2004 Dec; 94(9):1226-9. PubMed ID: 15610094
    [No Abstract]   [Full Text] [Related]  

  • 18. Treating prostate cancer, Part II: determining its severity.
    Harv Mens Health Watch; 2008 Jun; 12(11):1-4. PubMed ID: 18807624
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment.
    Suardi N
    J Urol; 2010 Feb; 183(2):545. PubMed ID: 20006873
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment on: predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance.
    Adolfsson J
    Eur Urol; 2008 Dec; 54(6):1304-5. PubMed ID: 18342429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.